Financials Kobayashi Pharmaceutical Co., Ltd.

Equities

4967

JP3301100008

Personal Products

Market Closed - Japan Exchange 02:00:00 2024-07-12 am EDT 5-day change 1st Jan Change
5,626 JPY -0.07% Intraday chart for Kobayashi Pharmaceutical Co., Ltd. +5.99% -17.14%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 724,573 985,637 704,427 650,295 503,841 418,231 - -
Enterprise Value (EV) 1 634,907 891,987 596,011 546,554 424,992 345,547 339,136 329,741
P/E ratio 38 x 51.3 x 35.8 x 34.8 x 25.3 x 26.9 x 21.4 x 20.5 x
Yield 0.79% 0.61% 0.92% 1% 1.49% 1.83% 1.87% 1.92%
Capitalization / Revenue 4.31 x 6.55 x 4.54 x 3.91 x 2.9 x 2.4 x 2.27 x 2.17 x
EV / Revenue 3.78 x 5.93 x 3.84 x 3.29 x 2.45 x 1.99 x 1.84 x 1.71 x
EV / EBITDA 20.8 x 29.7 x 19.3 x 17.1 x 13.3 x 10.7 x 10 x 9.25 x
EV / FCF 45.3 x 101 x 31.8 x 31.1 x -350 x 30.1 x 29.2 x 18.4 x
FCF Yield 2.21% 0.99% 3.15% 3.22% -0.29% 3.32% 3.43% 5.44%
Price to Book 4.2 x 5.4 x 3.59 x 3.47 x 2.47 x 2.01 x 1.88 x 1.78 x
Nbr of stocks (in thousands) 78,163 78,163 77,923 72,015 74,203 74,339 - -
Reference price 2 9,270 12,610 9,040 9,030 6,790 5,626 5,626 5,626
Announcement Date 1/31/20 2/1/21 2/4/22 2/14/23 2/9/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 168,052 150,514 155,252 166,258 173,455 174,054 184,504 192,443
EBITDA 1 30,482 30,049 30,900 32,027 31,837 32,365 33,905 35,633
EBIT 1 26,355 25,943 26,065 26,669 25,780 25,173 25,090 26,459
Operating Margin 15.68% 17.24% 16.79% 16.04% 14.86% 14.46% 13.6% 13.75%
Earnings before Tax (EBT) 1 26,804 26,635 27,636 27,950 27,559 24,361 27,471 28,945
Net income 1 19,139 19,205 19,715 20,022 20,338 15,684 19,621 20,566
Net margin 11.39% 12.76% 12.7% 12.04% 11.73% 9.01% 10.63% 10.69%
EPS 2 244.1 245.7 252.4 259.6 268.2 209.3 262.3 275.1
Free Cash Flow 1 14,016 8,870 18,756 17,601 -1,216 11,465 11,622 17,928
FCF margin 8.34% 5.89% 12.08% 10.59% -0.7% 6.59% 6.3% 9.32%
FCF Conversion (EBITDA) 45.98% 29.52% 60.7% 54.96% - 35.43% 34.28% 50.31%
FCF Conversion (Net income) 73.23% 46.19% 95.14% 87.91% - 73.1% 59.23% 87.17%
Dividend per Share 2 73.00 77.00 83.00 90.00 101.0 103.0 105.0 107.9
Announcement Date 1/31/20 2/1/21 2/4/22 2/14/23 2/9/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2
Net sales 1 94,422 66,180 84,334 67,052 47,594 88,200 32,646 38,618 71,264 43,015 51,979 94,994 33,467 40,158 73,625 45,490 54,340 99,830 36,485 38,356 76,100 45,297 52,378 101,900 - -
EBITDA - - - - - - - - - - - - - - - - - - - - - - - - - -
EBIT 1 14,934 10,220 15,723 10,240 6,639 15,825 4,845 5,023 9,868 8,881 7,920 16,801 5,061 5,345 10,406 8,981 6,393 15,374 5,028 5,375 12,500 8,390 5,758 16,500 - -
Operating Margin 15.82% 15.44% 18.64% 15.27% 13.95% 17.94% 14.84% 13.01% 13.85% 20.65% 15.24% 17.69% 15.12% 13.31% 14.13% 19.74% 11.76% 15.4% 13.78% 14.01% 16.43% 18.52% 10.99% 16.19% - -
Earnings before Tax (EBT) - 10,882 - 11,037 - - 5,097 - 10,860 9,510 7,580 - 5,097 5,968 11,065 10,073 - - 1,586 - - - - - - -
Net income 1 10,937 8,218 - 7,881 4,832 11,834 3,473 4,227 7,700 6,800 5,522 - 3,608 4,256 7,864 7,634 4,840 - 976 3,674 - 5,777 4,587 - - -
Net margin 11.58% 12.42% - 11.75% 10.15% 13.42% 10.64% 10.95% 10.8% 15.81% 10.62% - 10.78% 10.6% 10.68% 16.78% 8.91% - 2.68% 9.58% - 12.75% 8.76% - - -
EPS 2 - 105.1 - 100.8 61.94 - 44.87 54.68 99.55 87.97 72.11 - 47.43 55.92 103.4 100.3 64.52 - 13.13 53.15 - 70.90 73.35 - - -
Dividend per Share 2 - 34.00 - 37.00 46.00 - - 38.00 38.00 - 52.00 - - 43.00 43.00 - 58.00 - - 44.00 - - 59.00 - - 45.00
Announcement Date 1/31/20 7/30/20 2/1/21 7/29/21 2/4/22 2/4/22 4/27/22 8/3/22 8/3/22 11/1/22 2/14/23 2/14/23 5/10/23 8/8/23 8/8/23 11/7/23 2/9/24 2/9/24 5/10/24 - - - - - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 89,666 93,650 108,416 103,741 78,849 72,683 79,095 88,489
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 14,016 8,870 18,756 17,601 -1,216 11,465 11,622 17,928
ROE (net income / shareholders' equity) 11.3% 10.8% 10.4% 10.2% 10.1% 7.75% 9.06% 9.04%
ROA (Net income/ Total Assets) 12% 11.8% 11.4% 11.1% 10.4% 5.86% 6.72% 6.69%
Assets 1 159,562 163,389 172,738 179,958 194,711 267,587 292,062 307,273
Book Value Per Share 2 2,209 2,336 2,516 2,600 2,749 2,802 2,997 3,162
Cash Flow per Share 2 292.0 295.0 303.0 316.0 333.0 304.0 394.0 435.0
Capex 1 6,073 15,116 5,278 15,794 26,887 14,517 13,680 8,736
Capex / Sales 3.61% 10.04% 3.4% 9.5% 15.5% 8.34% 7.41% 4.54%
Announcement Date 1/31/20 2/1/21 2/4/22 2/14/23 2/9/24 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
5,626 JPY
Average target price
5,941 JPY
Spread / Average Target
+5.61%
Consensus
  1. Stock Market
  2. Equities
  3. 4967 Stock
  4. Financials Kobayashi Pharmaceutical Co., Ltd.